Ocular Rosacea
Definition
The ocular manifestation of rosacea, a chronic inflammatory skin condition, characterized by lid margin telangiectasia, meibomian gland dysfunction, recurrent chalazia, conjunctival injection, and in severe cases, corneal neovascularization and scarring.
Clinical Snapshot
Ocular rosacea is the ophthalmic manifestation of rosacea — a chronic, relapsing inflammatory condition of the skin and ocular adnexa. Ocular involvement occurs in 58–72% of rosacea patients and may precede, accompany, or occur independently of cutaneous disease. It is frequently underdiagnosed because eye care providers may not recognize the cutaneous signs, and dermatologists may not examine the eyes. Untreated, it can progress to corneal neovascularization and scarring with significant visual consequences.
Epidemiology
Rosacea affects approximately 5% of the global population, with higher prevalence in fair-skinned individuals of Northern European descent. Ocular involvement occurs in the majority of rosacea patients. It predominantly affects adults aged 30–60 and is more common in women, though men tend to have more severe disease.
Pathophysiology
The pathophysiology of rosacea involves dysregulation of innate immune responses, neurovascular dysfunction, and altered skin microbiome. Cathelicidin antimicrobial peptides (particularly LL-37) are overexpressed and processed into pro-inflammatory forms by kallikrein-5. Demodex mites carry Bacillus oleronius, which triggers immune responses. In the eye, these mechanisms produce lid margin telangiectasia, meibomian gland inflammation and dysfunction, and in severe cases, corneal neovascularization driven by VEGF upregulation.
Risk Factors
- Cutaneous rosacea (present in the majority of ocular rosacea patients)
- Fair skin and Northern European ancestry
- Female sex (higher prevalence, though males have more severe disease)
- Demodex infestation
- Triggers: UV exposure, heat, alcohol, spicy foods, emotional stress
Clinical Presentation
Lid margin telangiectasia is the hallmark sign — fine, dilated vessels at the posterior lid margin are pathognomonic. Meibomian gland dysfunction with turbid or absent meibum is nearly universal. Recurrent chalazia and hordeola are common. Conjunctival injection, papillary reaction, and superficial punctate keratopathy reflect ocular surface involvement. In severe cases, corneal neovascularization, marginal infiltrates, and corneal scarring may develop. Patients often report chronic burning, foreign body sensation, and photophobia.
Diagnostic Pearls
- Lid margin telangiectasia is the pathognomonic sign — examine the posterior lid margin carefully with the slit lamp.
- Ocular rosacea may present without obvious cutaneous disease — examine the face for erythema, telangiectasia, and rhinophyma.
- Recurrent chalazia in an adult should prompt evaluation for rosacea and Demodex.
- Corneal involvement (neovascularization, marginal infiltrates) indicates severe disease requiring aggressive management.
Differential Diagnosis
- Meibomian gland dysfunction (often coexistent)
- Staphylococcal blepharitis
- Demodex blepharitis
- Seborrheic blepharitis
- Atopic keratoconjunctivitis
Evidence-Based Management
Management targets both the lid margin inflammation and the systemic rosacea. Lid hygiene with warm compresses and hypochlorous acid cleansers is foundational. Oral doxycycline (50–100 mg daily) is the primary systemic therapy — its anti-inflammatory properties (MMP inhibition, lipase inhibition) are as important as its antimicrobial effect. Topical azithromycin (AzaSite®) provides local antibiotic and anti-inflammatory benefit. Topical metronidazole or azelaic acid addresses cutaneous rosacea in co-management with dermatology. Demodex should be actively screened and treated. Corneal involvement requires topical corticosteroids and close monitoring.
Monitoring & Follow-Up
Follow-up at 4–8 weeks after initiating therapy, then every 3–6 months for stable disease. Monitor for corneal neovascularization and marginal infiltrates — these indicate disease progression requiring escalation of therapy.
Clinical Pearls
- Ocular rosacea may be the presenting manifestation — eye care providers must recognize the cutaneous signs and co-manage with dermatology.
- Recurrent chalazia in adults are a red flag for rosacea — evaluate the lid margins and face carefully.
- Oral doxycycline's benefit in rosacea is primarily anti-inflammatory, not antimicrobial — sub-antimicrobial doses (40 mg modified-release) are effective and reduce resistance concerns.
- Demodex and rosacea frequently coexist — treat both simultaneously for optimal outcomes.
Related Therapeutics — Clinician's Companion
- Oral Therapeutics — Doxycycline (Clinician's Companion)
- Lid Margin & Demodex — Xdemvy®, AzaSite®, Lid Hygiene (Clinician's Companion)
- Anti-inflammatory Rescue — FML®, TobraDex® (Clinician's Companion)
Key References
- 1.Gallo RL, et al. Standard classification and pathophysiology of rosacea. J Am Acad Dermatol. 2018.
- 2.Vieira AC, et al. Ocular rosacea. Curr Opin Ophthalmol. 2012.
- 3.Two AM, et al. Rosacea: part I. J Am Acad Dermatol. 2015.
This entry is an educational reference designed to support clinical reasoning and awareness. It does not constitute medical advice, establish a standard of care, or replace individualized patient assessment. Clinicians should consult current guidelines and applicable clinical resources when making patient care decisions.